We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Galectin-3 Associated with Poor Prognosis in Cardiopathy Patients

By LabMedica International staff writers
Posted on 18 Jul 2013
Print article
Image: Galectin-3 test kit (Photo courtesy of BG Medicine Inc.).
Image: Galectin-3 test kit (Photo courtesy of BG Medicine Inc.).
The soluble β-galactoside-binding lectin, galectin-3, is elevated in a substantial portion of patients with heart failure, especially those with more severe disease and renal dysfunction.

Increased levels of circulating galectin-3 may reflect the severity of active myocardial remodeling and adverse outcome as galectin-3 regulates fibrogenesis, inflammation, tissue repair, and cell proliferation.

Scientists and cardiologists at the Veterans Administration Medical Center (Minneapolis, MN, USA) conducted a randomized, placebo-controlled, double-blind, multicenter trial that enrolled 5,010 patients with symptomatic heart failure (HF) to evaluate the efficacy of the angiotensin receptor blocker (ARB) valsartan. They measured galectin-3 and other biomarkers such as high-sensitivity C-reactive protein, high-sensitivity troponin, and B-type natriuretic peptide at three time points in a subpopulation of the trial patients. The time points were at baseline at 4 and 12 months after randomization.

Plasma samples from the patients were analyzed and galectin-3 was measured using an enzyme-linked immunosorbent assay (ELISA) (BG Medicine Inc.; Waltham, MA, USA). Galectin-3 levels at baseline ranged from 4.8 to 53 ng/mL. The median baseline galectin-3 level in 1,650 patients was 16.2 ng/mL, and levels increased significantly from baseline. At 4 months, the level increased by 1.0 ng/mL and by 12 months it had risen by 2.2 ng/mL. Each 1 ng/mL increase in galectin-3 was associated with an estimated 2.9% higher risk of mortality, 2.1% increased risk of first morbid event, and 2.2% greater risk of heart failure hospitalization.

The authors concluded that galectin-3 levels are elevated in a substantial proportion of patients with HF, particularly those with more severe HF and renal impairment. Median galectin-3 levels increased over time, and the magnitude of these serial increases was found to be independently and significantly associated with poorer HF outcomes. In patients with baseline galectin-3 levels below the median, use of valsartan was associated with a significant decrease in hospitalizations for heart failure. The study was published in the May 2013 issue of the European Journal of Heart Failure.

Related Links:
Veterans Administration Medical Center
BG Medicine Inc.

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Vaginitis Test
Allplex Vaginitis Screening Assay
New
TORCH Infections Test
TORCH Panel

Print article

Channels

Molecular Diagnostics

view channel
Image: Researcher Kanta Horie places a sample in a mass spectrometer that measures protein levels in blood plasma and other fluids (Photo courtesy of WashU Medicine)

Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression

Several blood tests are currently available to assist doctors in diagnosing Alzheimer's disease in individuals experiencing cognitive symptoms. However, these tests do not provide insights into the clinical... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.